Holen Sie sich die Stockscreener-App
0.3469
4.39%
0.0146
Schlusskurs vom Vortag:
$0.3323
Offen:
$0.3306
24-Stunden-Volumen:
1.10M
Relative Volume:
1.16
Marktkapitalisierung:
$91.95M
Einnahmen:
$175.04M
Nettoeinkommen (Verlust:
$-44.52M
KGV:
-1.9272
EPS:
-0.18
Netto-Cashflow:
$-56.05M
1W Leistung:
+24.11%
1M Leistung:
+37.11%
6M Leistung:
-41.39%
1J Leistung:
-73.32%
1-Tages-Spanne:
$0.33
$0.3539
1-Wochen-Bereich:
$0.2651
$0.3578
52-Wochen-Spanne:
$0.1951
$1.48
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Company Profile
Firmenname
Adaptimmune Therapeutics Plc Adr
Sektor
Branche
Telefon
44 1235 430000
Adresse
60 JUBILEE AVENUE, ABINGDON, OXFORDSHIRE
Vergleichen Sie ADAP mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ADAP
Adaptimmune Therapeutics Plc Adr
|
0.3469 | 88.08M | 175.04M | -44.52M | -56.05M | -0.18 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Adaptimmune Therapeutics Plc Adr Stock (ADAP) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-26 | Herabstufung | Mizuho | Outperform → Neutral |
| 2024-07-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-05-30 | Eingeleitet | Scotiabank | Sector Outperform |
| 2023-03-24 | Eingeleitet | Bryan Garnier | Buy |
| 2023-01-03 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-11-09 | Hochstufung | Mizuho | Neutral → Buy |
| 2021-05-28 | Eingeleitet | Barclays | Underweight |
| 2020-04-22 | Eingeleitet | Mizuho | Neutral |
| 2019-08-02 | Herabstufung | Guggenheim | Buy → Neutral |
| 2019-05-31 | Eingeleitet | ROTH Capital | Buy |
| 2019-05-30 | Fortgesetzt | Citigroup | Buy |
| 2019-05-07 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2017-03-17 | Eingeleitet | Wells Fargo | Market Perform |
| 2016-10-24 | Herabstufung | BofA/Merrill | Neutral → Underperform |
| 2016-09-30 | Eingeleitet | Raymond James | Outperform |
| 2016-02-25 | Eingeleitet | Citigroup | Buy |
| 2015-06-01 | Eingeleitet | BofA/Merrill | Neutral |
| 2015-06-01 | Eingeleitet | Guggenheim | Buy |
| 2015-06-01 | Eingeleitet | Leerink Partners | Outperform |
Alle ansehen
Adaptimmune Therapeutics Plc Adr Aktie (ADAP) Neueste Nachrichten
Mizuho downgrades Adaptimmune stock on solvency concerns - Investing.com
Financial Metrics Unveiled: MARA Holdings Inc (MARA)’s Key Ratios in the Spotlight - DWinneX
Context Therapeutics names new CMO to advance T cell therapies By Investing.com - Investing.com South Africa
Context Therapeutics names new CMO to advance T cell therapies - Investing.com
Adaptimmune Therapeutics earnings beat by $0.09, revenue fell short of estimates - Investing.com UK
Healthy Upside Potential: Merus N.V (MRUS) - Sete News
How should investors view Jianzhi Education Technology Group Co Ltd ADR (JZ)? - uspostnews.com
All Markets & Instruments Available to Trade - Capital.com
Adaptimmune Therapeutics Plc ADR’s (ADAP) Stock Is Harder To Predict Than You Think - Stocksregister
Take off with Adaptimmune Therapeutics Plc ADR (ADAP): Get ready for trading - Sete News
ADAP (Adaptimmune Therapeutics Plc ADR) may reap gains as insiders became active recently - knoxdaily.com
AUTL’s Market Whiplash: -44.26% YTD Decline, -21.08% Plunge in 30 Days - investchronicle.com
Adaptimmune Therapeutics Plc ADR (ADAP) Stock: Navigating Drops and Gains - investchronicle.com
ADAP underperforms with a -5.05 decrease in share price - uspostnews.com
Closing Figures: Myriad Genetics, Inc (MYGN)’s Negative Finish at 7.20, Down -4.00 - DWinneX
Stock Performance Spotlight: Adaptimmune Therapeutics Plc ADR (ADAP) Ends the Day at 0.26, Down by -5.05 - DWinneX
Let’s Jump Into The Geron Corp (NASDAQ: GERN) Stock Forecast - Marketing Sentinel
Bausch + Lomb Corp (NYSE:BLCO)’s 12-Month Price Target Is Now Set At 23. - Marketing Sentinel
B. Riley Financial Inc (NASDAQ:RILY) Shares Dropped -2.22% In A Week. Can It Continue Rising? - Marketing Sentinel
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) Could Really Rise To 4 In 12 Months, According To Analysts. - Marketing Sentinel
Is Live Oak Bancshares Inc (NYSE:LOB) A Better Buy Than Others After A -32.27% Fall In This Year? - Marketing Sentinel
Eventbrite Inc (NYSE:EB) Declines -81.18% In 2025; Are Investors Attracted By Its $2.10 Price? - Marketing Sentinel
The Adaptimmune Therapeutics Plc ADR (ADAP) had a good session last reading, didn’t it? - uspostnews.com
How should investors view Lazard Inc (LAZ)? - uspostnews.com
Olema Pharmaceuticals Inc (OLMA)’s results reveal risk - uspostnews.com
It would be worthwhile to take a closer look at Quantum Corp (QMCO) - uspostnews.com
Was there any good news for Neuronetics Inc (STIM) stock in the last session? - uspostnews.com
TransCode Therapeutics Inc: Weathering Stock Market Storms with 8.59M Market Cap - investchronicle.com
Charting the Course: Tempest Therapeutics Inc’s TPST Stock Prospects - investchronicle.com
Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) Today’s Hot Stock - stocksregister.com
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Adaptimmune stock target to $3, maintains Buy - Investing.com India
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy By Investing.com - Investing.com South Africa
Guggenheim cuts Adaptimmune target to $1.75, maintains Buy - Investing.com
Adaptimmune Therapeutics Amends Loan Agreement By Investing.com - Investing.com India
Adaptimmune Therapeutics Amends Loan Agreement - Investing.com
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating By Investing.com - Investing.com South Africa
Scotiabank cuts Adaptimmune price target to $1.40, keeps rating - Investing.com
United States shares lower at close of trade; Dow Jones Industrial Average down 0.03% - Investing.com India
Mizuho maintains Outperform on Adaptimmune, price target $1.50 By Investing.com - Investing.com South Africa
Mizuho maintains Outperform on Adaptimmune, price target $1.50 - Investing.com
Earnings call transcript: Adaptimmune Q4 2024 targets $25M sales in 2025 - Investing.com
Adaptimmune Therapeutics Plc ADR (ADAP)’s Stock Price Falls Due To Weak Fundamental Momentum - Marketing Sentinel
Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call - ACCESS Newswire
LAG-3 Immunotherapies Market Set for Rapid Growth in the Coming 10 Years Across the 7MM as Next-Generation Therapies Advance | DelveInsight - GlobeNewswire Inc.
Analysts Recommend Holding Your Position In Adaptimmune Therapeutics Plc ADR (NASDAQ: ADAP) - Stocks Register
Investing in Adaptimmune Therapeutics Plc ADR (ADAP) Is Getting More Attractive - Knox Daily
Potential Price Increase for Coterra Energy Inc (CTRA) After Recent Insider Activity - Knox Daily
Taking a Closer Look At Dollar Tree Inc (DLTR) Following Its Recent Trade - Knox Daily
A Guide To The Risks Of Investing In Agilon Health Inc (AGL) - Knox Daily
Daily Progress: Quanterix Corp (QTRX) Drop -3.57, Closing at 7.83 - The Dwinnex
Finanzdaten der Adaptimmune Therapeutics Plc Adr-Aktie (ADAP)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.97%
0.22%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):